Hemarina SA opened Phase II clinical trials on Tuesday for HEMO2life, a synthetic oxygen carrier derived from lugworm hemoglobin, enrolling 240 trauma patients across twelve U.S. emergency departments. The study tests whether the substitute reduces organ failure when administered before hospital arrival, addressing a gap in rural and battlefield medicine where blood refrigeration chains break down.

Principal investigator Dr. Maria Santos at Harborview Medical Center in Seattle said donated blood remains the gold standard but stockouts during mass-casualty events and remote accidents kill patients who could survive with temporary oxygen delivery. Hemarina's product is stable at room temperature for months.

Mechanism

Natural hemoglobin from Arenicola marina carries oxygen at lower affinity than human hemoglobin, releasing oxygen in hypoxic tissues without requiring cross-matching. Earlier Phase I data showed acceptable pharmacokinetics and no acute anaphylaxis in healthy volunteers.

Competing programs from OxyVita and Sangart pursued polymerized hemoglobin with mixed results in the 2000s; regulators remain cautious after prior substitutes increased stroke risk in some trials. Hemarina argues marine hemoglobin's molecular structure avoids those pitfalls.

Trial Design

Patients with hemorrhagic shock receive either standard care plus HEMO2life or standard care alone in a randomized protocol. The primary endpoint is 28-day survival without multi-organ dysfunction. An independent data safety monitoring board will review interim results after 120 enrollments.

The Department of Defense co-funded the trial through a Cooperative Research and Development Agreement, reflecting military interest in far-forward medics without blood banks.

Regulatory Path

The Food and Drug Administration granted fast-track designation in April based on unmet need in pre-hospital trauma. Approval timelines depend on effect size; even modest survival gains could support conditional authorization for military and rural EMS systems.

Blood bank organizations including America's Blood Centers requested dialogue on whether substitutes complement or cannibalize donation drives. Hemarina executives say substitutes target settings where blood is unavailable, not hospital replacements.

Commercial Outlook

Trauma care markets are smaller than oncology but carry premium pricing if outcomes improve. Hemarina has discussed manufacturing scale-up with contract partners in France and North Carolina.

Success would mark the first widely validated synthetic oxygen carrier in decades. Failure would reinforce skepticism that blood replacement is an intractable biomedical problem despite advances elsewhere in regenerative medicine.

Rural emergency medical services directors in Montana and Alaska joined the trial network, citing average blood delivery times exceeding 90 minutes during winter storms. Hemarina plans companion studies in postpartum hemorrhage if trauma endpoints succeed, a larger patient population that could transform commercial economics if regulators approve broader indications.

Ethics and Access

Bioethicists on the trial's advisory board required explicit consent language explaining that substitutes remain experimental and that donated blood may still be preferred when available. Community hospitals in tribal nations joined the network under Indian Health Service oversight, addressing historical mistrust in federally funded medical research.

If trials succeed, pricing strategy will determine whether substitutes reach ambulance services in low-income counties or remain limited to military and urban trauma centers with premium budgets.

Interim analysis after 120 patients could read out before year-end if enrollment stays on pace across participating trauma centers.